Amgen, Inc. (AMGN) Shares Bought by Legacy Private Trust Co.

Amgen, Inc. (AMGN) Shares Bought by Legacy Private Trust Co.

Legacy Private Trust Co. raised its holdings in Amgen, Inc. (NASDAQ:AMGN) by 4.1% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 7,997 shares of the medical research company’s stock after purchasing an additional 315 shares during the quarter. Legacy Private Trust Co.’s holdings in Amgen were worth $1,391,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of the business. Janus Henderson Group PLC raised its holdings in shares of Amgen by 3,664.7% in the 2nd quarter. Janus Henderson Group PLC now owns 3,699,351 shares of the medical research company’s stock valued at $637,139,000 after buying an additional 3,601,087 shares during the period. FMR LLC raised its holdings in shares of Amgen by 4.8% in the 2nd quarter. FMR LLC now owns 56,999,572 shares of the medical research company’s stock valued at $9,817,037,000 after buying an additional 2,587,041 shares during the period. Renaissance Technologies LLC raised its holdings in shares of Amgen by 40.9% in the 2nd quarter. Renaissance Technologies LLC now owns 3,400,145 shares of the medical research company’s stock valued at $585,607,000 after buying an additional 986,700 shares during the period. BlackRock Inc. raised its holdings in shares of Amgen by 1.9% in the 2nd quarter. BlackRock Inc. now owns 49,451,203 shares of the medical research company’s stock valued at $8,516,980,000 after buying an additional 909,689 shares during the period. Finally, Nordea Investment Management AB raised its holdings in shares of Amgen by 12.9% in the 2nd quarter. Nordea Investment Management AB now owns 7,040,599 shares of the medical research company’s stock valued at $1,212,602,000 after buying an additional 806,119 shares during the period. Institutional investors own 78.03% of the company’s stock.

Several research analysts recently commented on AMGN shares. Goldman Sachs Group cut Amgen from a “conviction-buy” rating to a “buy” rating in a research note on Friday, December 15th. Oppenheimer set a $205.00 target price on Amgen and gave the stock a “buy” rating in a research note on Tuesday, December 12th. Mizuho set a $198.00 target price on Amgen and gave the stock a “buy” rating in a research note on Sunday, October 29th. Zacks Investment Research raised Amgen from a “hold” rating to a “buy” rating and set a $199.00 target price for the company in a research note on Friday, October 27th. Finally, Cann reissued a “buy” rating and set a $205.00 target price on shares of Amgen in a research note on Thursday, November 30th. Sixteen investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. Amgen has an average rating of “Hold” and an average price target of $191.84.

Shares of Amgen, Inc. (NASDAQ AMGN) opened at $183.55 on Monday. The stock has a market capitalization of $132,259.19, a PE ratio of 14.59, a P/E/G ratio of 2.19 and a beta of 1.42. The company has a debt-to-equity ratio of 1.35, a current ratio of 5.49 and a quick ratio of 5.17. Amgen, Inc. has a 1 year low of $152.16 and a 1 year high of $201.23.

Amgen (NASDAQ:AMGN) last announced its earnings results on Thursday, February 1st. The medical research company reported $2.89 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.03 by ($0.14). The firm had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.84 billion. Amgen had a net margin of 8.66% and a return on equity of 30.87%. The firm’s revenue for the quarter was down 2.7% compared to the same quarter last year. During the same period last year, the company earned $2.89 earnings per share. research analysts anticipate that Amgen, Inc. will post 13.21 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 8th. Investors of record on Thursday, February 15th will be given a $1.32 dividend. The ex-dividend date of this dividend is Wednesday, February 14th. This is a boost from Amgen’s previous quarterly dividend of $1.15. This represents a $5.28 dividend on an annualized basis and a dividend yield of 2.88%. Amgen’s dividend payout ratio is 205.45%.

Amgen announced that its Board of Directors has initiated a share repurchase plan on Wednesday, October 25th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the medical research company to repurchase shares of its stock through open market purchases. Shares repurchase plans are generally an indication that the company’s leadership believes its shares are undervalued.

In related news, EVP Sean E. Harper sold 1,525 shares of the company’s stock in a transaction dated Tuesday, December 12th. The stock was sold at an average price of $176.83, for a total value of $269,665.75. Following the completion of the sale, the executive vice president now directly owns 56,106 shares of the company’s stock, valued at approximately $9,921,223.98. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Over the last three months, insiders sold 4,575 shares of company stock valued at $818,361. Insiders own 0.19% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This news story was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States & international copyright & trademark legislation. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2018/02/19/amgen-inc-amgn-shares-bought-by-legacy-private-trust-co.html.

Amgen Company Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.

Legacy Private Trust Co. raised its holdings in Amgen, Inc. (NASDAQ:AMGN) by 4.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 7,997 shares of the medical research company’s stock after purchasing an additional 315 shares during the period. Legacy Private Trust Co.’s holdings in Amgen were worth $1,391,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of AMGN. Toronto Dominion Bank boosted its stake in shares of Amgen by 11.0% in the third quarter. Toronto Dominion Bank now owns 279,280 shares of the medical research company’s stock worth $52,066,000 after acquiring an additional 27,726 shares during the last quarter. Welch Group LLC acquired a new stake in shares of Amgen in the second quarter worth approximately $639,000. DekaBank Deutsche Girozentrale boosted its stake in shares of Amgen by 2.8% in the second quarter. DekaBank Deutsche Girozentrale now owns 883,579 shares of the medical research company’s stock worth $152,927,000 after acquiring an additional 24,219 shares during the last quarter. Pacer Advisors Inc. boosted its stake in shares of Amgen by 10.3% in the second quarter. Pacer Advisors Inc. now owns 25,378 shares of the medical research company’s stock worth $4,371,000 after acquiring an additional 2,362 shares during the last quarter. Finally, Teacher Retirement System of Texas boosted its stake in shares of Amgen by 16.5% in the third quarter. Teacher Retirement System of Texas now owns 740,764 shares of the medical research company’s stock worth $138,115,000 after acquiring an additional 104,871 shares during the last quarter. 78.03% of the stock is currently owned by institutional investors.

In other Amgen news, EVP Sean E. Harper sold 1,525 shares of Amgen stock in a transaction on Wednesday, February 14th. The stock was sold at an average price of $174.18, for a total value of $265,624.50. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders sold 4,575 shares of company stock worth $818,361 in the last 90 days. Company insiders own 0.19% of the company’s stock.

Shares of Amgen, Inc. (NASDAQ:AMGN) opened at $183.55 on Monday. Amgen, Inc. has a 1 year low of $152.16 and a 1 year high of $201.23. The company has a quick ratio of 5.17, a current ratio of 5.49 and a debt-to-equity ratio of 1.35. The company has a market capitalization of $132,259.19, a price-to-earnings ratio of 14.59, a price-to-earnings-growth ratio of 2.19 and a beta of 1.42.

Amgen (NASDAQ:AMGN) last posted its earnings results on Thursday, February 1st. The medical research company reported $2.89 EPS for the quarter, missing the Zacks’ consensus estimate of $3.03 by ($0.14). Amgen had a net margin of 8.66% and a return on equity of 30.87%. The business had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.84 billion. During the same quarter in the prior year, the firm earned $2.89 EPS. Amgen’s revenue for the quarter was down 2.7% compared to the same quarter last year. equities research analysts expect that Amgen, Inc. will post 13.21 EPS for the current fiscal year.

Amgen announced that its board has approved a share buyback plan on Wednesday, October 25th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the medical research company to buy shares of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s leadership believes its shares are undervalued.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 8th. Shareholders of record on Thursday, February 15th will be given a $1.32 dividend. The ex-dividend date of this dividend is Wednesday, February 14th. This represents a $5.28 dividend on an annualized basis and a yield of 2.88%. This is an increase from Amgen’s previous quarterly dividend of $1.15. Amgen’s payout ratio is currently 205.45%.

A number of analysts have recently issued reports on AMGN shares. Zacks Investment Research raised Amgen from a “hold” rating to a “buy” rating and set a $199.00 price target on the stock in a research note on Friday, October 27th. Citigroup lowered Amgen to a “neutral” rating in a research note on Monday, December 18th. Royal Bank of Canada lowered their price target on Amgen from $192.00 to $188.00 and set a “sector perform” rating on the stock in a research note on Thursday, October 26th. Goldman Sachs Group lowered Amgen from a “conviction-buy” rating to a “buy” rating in a research note on Friday, December 15th. Finally, Argus raised Amgen from a “hold” rating to a “buy” rating and lifted their price target for the stock from $192.33 to $220.00 in a research note on Tuesday, January 23rd. Sixteen research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $191.84.

ILLEGAL ACTIVITY NOTICE: “Amgen, Inc. (AMGN) Shares Bought by Legacy Private Trust Co.” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another domain, it was copied illegally and republished in violation of United States & international copyright & trademark law. The correct version of this piece can be accessed at https://www.dispatchtribunal.com/2018/02/19/amgen-inc-amgn-shares-bought-by-legacy-private-trust-co.html.

About Amgen

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply